What does the mechanism of semaglutide predict that SELECT did not test?

Conditions: semaglutide · SELECT.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Why does this happen, and what would falsify the usual explanation?

In practice, the mechanism question has a clean answer for the peripheral effects and a much less clean answer for the central ones, and it is worth being explicit about which of those you are asking about.

Orforglipron is not a peptide at all, which changes everything downstream: it is orally bioavailable without an absorption enhancer, it has no fasting or water requirement of the same kind, it does not require cold chain, and it cannot be assayed by any of the peptide methods discussed elsewhere on this site.

What each test answers

What the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.

The role of the area postrema and the hypothalamic arcuate nucleus in GLP-1-mediated appetite suppression is supported by both the neuroanatomy of receptor expression and by the effect of lesioning studies in animal models.

Do not convert doses between agents. There is no exchange rate, and constructing one is how people arrive at an order-of-magnitude error.

The half-life is a formulation achievement rather than an intrinsic property. Native GLP-1 has a plasma half-life of a couple of minutes; everything in this class is a set of modifications engineered to defeat that.

Tirzepatide is an imbalanced dual agonist: it is more potent at the GIP receptor than at the GLP-1 receptor, which is the opposite of what most people assume from the way it is described. Whether the GIP contribution works through central appetite pathways, through adipose insulin sensitisation, or through modulating the GLP-1 signal is genuinely unsettled, and the honest position is that the clinical result is clear and the attribution is not.

The Aib substitution at position 8 replaces alanine with α-aminoisobutyric acid, which is sterically hindered enough that dipeptidyl peptidase-4 cannot cleave the N-terminal dipeptide. That single change takes the half-life from minutes to hours. The C18 diacid on a linker at Lys26 then binds albumin reversibly, which both shields the molecule from renal filtration and creates a depot that releases slowly — taking hours to about a week.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

The mechanism is settled enough to be useful and unsettled enough to be interesting, which is a reasonable place for a field to be.

edited 17 Aug 2026 by Dr_Nadia_Farsi — corrected a unit error in the worked example

Stated carefully, two structural interventions do the work: substitution at the DPP-4 cleavage site to stop enzymatic degradation, and a fatty-acid chain to bind serum albumin and create a slowly released reservoir. Remove either and you are back to a compound requiring continuous infusion.

The split between delayed gastric emptying and central satiety matters because they have different time courses. Gastric emptying effects show substantial tachyphylaxis over weeks; the central appetite effect does not, or does so much more slowly. That dissociation is the best available explanation for why nausea fades while appetite suppression persists.

The GIP agonism-versus-antagonism question remains open, and the awkward fact is that both directions have produced weight loss in humans. The reconciling hypothesis is that chronic GIPR agonism produces receptor desensitisation and therefore functions as a pharmacological antagonist, but that is a hypothesis fitted to the data rather than an independent finding.

The limitation here is that almost all of the human mechanistic work is in the licensed agents, so mechanistic claims about the investigational tri-agonists rest on animal and early-phase data.

The chemistry is the interesting part and it is also the well-documented part. Read the medicinal chemistry papers; they are short and they explain the design.

Put another way, start from the receptor and the rest follows: which receptors, in what ratio, with what signalling bias, reached at what concentration.

Receptor desensitisation as a plateau mechanism is plausible and poorly evidenced. GLP-1R internalises on agonist binding and recycles, and biased agonists that internalise less have been argued to sustain signalling better. Whether any of that operates at the timescale of a four-month clinical plateau — against the much simpler explanation that energy expenditure fell with mass — is not established.

Worth noting that receptor pharmacology measured in a transfected cell line is a starting point, not a physiological measurement, and potency ratios do not transfer cleanly in vivo.

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.

Dose equivalence across agents with different receptor profiles is not a defensible concept, and the attempt to construct it is the most common analytical error in this area.

Comparing a 2.4 mg dose of one agonist to a 15 mg dose of another tells you nothing, because the molar potencies at their respective receptors differ, the receptor profiles differ, and the exposure per milligram differs. The only defensible comparison is between clinical outcomes in trials with comparable populations and durations, which is why SURMOUNT-5 exists and why indirect comparisons should be read sceptically.

I would separate what is established structurally from what is inferred clinically. The chemistry is settled; the attribution of clinical effect to specific receptor arms mostly is not.

Structure predicts pharmacokinetics reliably and clinical effect unreliably. Keep the two claims separate.

edited 23 Aug 2026 by nynke_dekker — fixed an arithmetic slip in the third paragraph